Table 3. Odds ratio (and 95% CI) of keratinocyte cancers occurring at specific anatomic sites among cases with melanoma of the head/neck, trunk, upper and lower limbs compared to controls with other solid tumours.
| Controls (N=349 923) |
Head and neck melanoma cases (N=512)
|
Trunk melanoma cases (N=1018)
|
Upper limb melanoma cases (N=749)
|
Lower limb melanoma cases (N=1569)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keratinocytic cancer site | % | % | OR (95% CI)a | Adj OR (95% CI)b | % | OR (95% CI)a | Adj OR (95% CI)b | % | OR (95% CI)a | Adj OR (95% CI)b | % | OR (95% CI)a | Adj OR (95% CI) |
| Head and neck | |||||||||||||
| All keratinocyte cancers | 2.46 | 10.35 | 4.58 (3.44–6.09) | 5.33 (3.97–7.14) | 3.44 | 1.41 (1.01–1.98) | 3.03 (2.15–4.27) | 4.14 | 1.71 (1.19–2.45) | 3.68 (2.55–5.31) | 2.74 | 1.12 (0.82–1.53) | 2.40 (1.75–3.29) |
| BCC onlyd | 2.15 | 9.49 | 4.77 (3.53–6.44) | 5.58 (4.10–7.60) | 3.44 | 1.62 (1.15–2.28) | 3.47 (2.45–4.92) | 3.34 | 1.57 (1.05–2.36) | 3.36 (2.22–5.08) | 2.50 | 1.17 (0.84–1.62) | 2.44 (1.74–3.41) |
| SCC onlyc | 0.39 | 1.97 | 5.16 (2.66–10.01) | 5.89 (3.02–11.51) | 0.63 | 1.62 (0.72–3.62) | 3.89 (1.73–8.74) | 0.72 | 1.85 (0.77–4.47) | 5.23 (2.15–12.71) | 0.28 | 0.73 (0.27–1.96) | 2.32 (0.87–6.24) |
| Trunk | |||||||||||||
| All keratinocyte cancers | 0.29 | 0.78 | 4.03 (1.50–10.82) | 4.44 (1.66–11.93) | 1.77 | 9.22 (5.75–14.78) | 12.48 (7.15–20.19) | 1.34 | 6.93 (3.70–12.99) | 9.87 (5.23–18.61) | 0.80 | 4.14 (2.37–7.35) | 6.04 (3.38–10.81) |
| BCC onlyd | 0.17 | 0.88 | 5.16 (1.92–13.85) | 5.81 (2.16–15.62) | 1.55 | 9.90 (5.43–15.24) | 12.32 (7.28–20.85) | 1.14 | 6.66 (3.30–13.43) | 9.42 (4.64–19.13) | 0.78 | 4.53 (2.49–8.24) | 6.48 (3.53–11.90) |
| SCC onlyc | 0.03 | 0.00 | N/C | N/C | 0.21 | 7.49 (1.84–30.44) | 11.94 (2.86–49.92) | 0.14 | 5.14 (0.72–36.95) | 9.83 (1.35–71.58) | 0.00 | N/C | N/C |
| Upper limbs | |||||||||||||
| All keratinocyte cancers | 0.15 | 0.59 | 3.95 (1.27–12.27) | 4.39 (1.40–13.71) | 0.79 | 5.28 (2.62–10.64) | 9.77 (4.81–19.84) | 1.07 | 7.19 (3.56–14.50) | 13.76 (6.76–28.00) | 0.27 | 1.79 (0.67–4.79) | 3.56 (1.32–9.59) |
| BCC onlyd | 0.07 | 0.00 | N/C | N/C | 0.63 | 9.66 (4.28–21.79) | 15.76 (6.90–36.02) | 0.43 | 6.63 (2.12–20.78) | 10.62 (3.35–33.67) | 0.14 | 2.19 (0.54–8.81) | 3.45 (0.85–14.08) |
| SCC onlyc | 0.09 | 0.44 | 5.06 (1.26–20.30) | 5.90 (1.46–23.84) | 0.10 | 1.18 (0.17–8.43) | 2.67 (0.37–19.11) | 0.14 | 1.62 (0.23–11.58) | 4.07 (0.57–29.09) | 0.07 | 0.80 (0.11–5.72) | 2.16 (0.30–15.40) |
| Lower limbs | |||||||||||||
| All keratinocyte cancers | 0.17 | 0.39 | 2.27 (0.56–9.11) | 2.49 (0.62–10.03) | 0.29 | 1.71 (0.55–5.32) | 3.85 (1.23–12.02) | 0.40 | 2.33 (0.75–7.25) | 3.85 (1.25–12.02) | 1.74 | 10.24 (6.89–15.21) | 14.39 (9.59–21.58) |
| BCC onlyd | 0.10 | 0.22 | 2.14 (0.30–15.30) | 2.47 (0.35–17.66) | 0.31 | 3.03 (0.97–9.44) | 6.26 (1.99–19.71) | 0.14 | 1.38 (0.19–9.87) | 2.22 (0.31–15.90) | 0.92 | 8.90 (5.11–15.52) | 12.07 (6.85–21.25) |
| SCC onlyc | 0.07 | 0.00 | N/C | N/C | 0.00 | N/C | N/C | 0.00 | N/C | N/C | 0.14 | 1.98 (0.49–7.88) | 3.27 (0.81–13.25) |
a
Odds ratio and 95% confidence interval. The reference group was people with no keratinocyte cancers in each analysis.
b
Odds ratio and 95% confidence interval adjusted for exact age (in years), age squared and sex.
c
In total, 9080 people were excluded from the SCC analysis because they had no SCC diagnosis but a diagnosis of another keratinocyte cancers.
d
In total, 1975 people were excluded from the BCC analysis because they had a diagnosis of a keratinocyte cancer other than BCC. N/C=not calculated due to a zero cell in the control group.